Quisinostat

DRUG4 trials

Sponsors

NewVac LLC, Nader Sanai, University of Miami

Conditions

Epithelial Ovarian CancerGlioblastoma WHO Grade IVNon-small Cell Lung CancerOvarian CancerUveal Melanoma

Early Phase 1

Phase 0 With Expansion Phase Clinical Trial of Quisinostat Plus Radiotherapy in Newly-diagnosed and Recurrent Grade 4 IDH-Wildtype Glioblastomas

Active, not recruitingNCT06824662

Nader SanaiGlioblastoma WHO Grade IV

Start: 2025-09-04End: 2028-01-14Target: 30Updated: 2026-03-17

Phase 1

Safety, Tolerability and Pharmacokinetics of Quisinostat, a Histone Deacetylase Inhibitor, in Combination With Chemotherapy

CompletedNCT02728492

NewVac LLCEpithelial Ovarian Cancer, Non-small Cell Lung Cancer

Start: 2013-08-31End: 2016-01-31Updated: 2016-05-03

Phase 2

Safety and Efficacy of Quisinostat, a Histone Deacetylase Inhibitor, in Combination With Chemotherapy

CompletedNCT02948075

NewVac LLCOvarian Cancer

Start: 2015-09-30End: 2017-06-16Updated: 2018-06-27

Adjuvant Quisinostat in High-Risk Uveal Melanoma

RecruitingNCT06932757

University of MiamiUveal Melanoma

Start: 2025-05-27End: 2030-05-27Target: 63Updated: 2026-06-18

Related Papers

A multicenter phase II study of the efficacy and safety of quisinostat (an HDAC inhibitor) in combination with paclitaxel and carboplatin chemotherapy (CT) in patients (pts) with recurrent platinum resistant high grade serous epithelial ovarian, primarily peritoneal or fallopian tube carcinoma cancer (OC).

Journal of Clinical Oncology2017-05-2016 citations